Results 21 to 30 of about 4,254 (200)
Osteonecrosis of the jaw as a serious adverse effect of bisphosphonate therapy and its indistinct etiopathogenesis [PDF]
Vojnosanitetski Pregled, 2014 nema
Gavrić Miodrag +6 more
doaj +1 more source
Drugs in Context, 2020 Background: On stopping bisphosphonate treatment, bone resorption may increase before evidence of a decrease in bone density. Offset of bisphosphonate effect may therefore be monitored by measuring C-terminal telopeptide (CTX) following long-term ...
Louise Statham +2 more
doaj +1 more source
Obesity influences the development of bisphosphonate-induced osteonecrosis in Wistar rats [PDF]
Journal of Applied Oral Science, 2023 Medication-related osteonecrosis of the jaw (MRONJ) is characterized by bone exposure for more than eight weeks in patients who have used or been treated with antiresorptive or antiangiogenic drugs, without a history of radiation therapy or metastatic ...
Wilson José de Miranda LIMA +7 more
doaj +1 more source
Diagnostics, 2021 Complex regional pain syndrome type I (CRPS I)—or algodystrophy—is a rare disease that usually occurs after a traumatic event. It is characterized by typical clinical findings such as severe and disabling pain disproportionate to the injury, functional ...
Antimo Moretti +6 more
doaj +1 more source
Use of disodium pamidronate bisphosphonate in patients with bone metastases of lung cancer [PDF]
Vojnosanitetski Pregled, 2002 Disodium pamidronate (Aredia®), a drug of the bisphosphonate group, was administered to 20 patients with pains in the bones due to secondary deposits of lung cancer.
Ranković Boško, Mrđa Vladimir
doaj +1 more source
Osteoporosis and Sarcopenia, 2022 Objectives: Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort.
Seihee Kim, Yoon-Sok Chung, Yunhwan Lee
doaj +1 more source
Effectiveness and safety of pamidronate treatment in nonambulatory children with low bone mineral density [PDF]
Annals of Pediatric Endocrinology & MetabolismPurpose Nonambulatory pediatric patients may have low bone mineral density (BMD) and increased risk of pathologic fractures. Though bisphosphonate therapy is the mainstream medical intervention in these children, clinical data regarding this treatment ...
Myeongseob Lee +7 more
doaj +1 more source
Journal of Oral Biology and Craniofacial Research, 2021 Background: Previous systematic reviews showed additional benefit of adjuvant bisphosphonates (BP) in the treatment of periodontitis. In contrast, it is unclear the effect of BP in patients with diabetes and smokers, its pooled effect when administered ...
Francisco Wilker Mustafa Gomes Muniz +4 more
doaj +1 more source
Effects of Sequential Anti-Resorptive Agents on Bone Mineral Density Following Denosumab Withdrawal: A Multicenter Real-World Study in Korea (MAXCARE Study) [PDF]
Endocrinology and MetabolismBackground Denosumab is a potent anti-resorptive agent widely used for osteoporosis. However, its discontinuation results in a ‘rebound phenomenon’ of rapid bone loss, necessitating transition to alternative anti-resorptive therapies. Despite this, there
Jeonghoon Ha +6 more
doaj +1 more source
Strontium Ranelate Elevates Expression of Heme Oxygenase-1 and Decreases Alveolar Bone Loss in Rats
eJournal of Oral Maxillofacial Research, 2018 Objectives: The purpose of this study was to determine the effects of strontium ranelate on ligature-induced periodontitis in rats and assess the putative involvement of heme oxygenase-1 (HO-1) pathway in these effects.
Ricardo Basto Souza +6 more
doaj +1 more source